Subhechcha Ganguly 
Imagine having the choice to live for 120 years. The attractive offer would likely be considered by many of us. By the end of the century, 150 will be considered normal thanks to the rapid advancements in stem cell technology, which make it possible for humans to live and even function much beyond what is currently thought to be possible.
Globally, human longevity has expanded significantly since 1900 as a result of significant advancements in science and healthcare. A number of diseases that were thought to be fatal a few decades ago have been conquered by humans thanks to the development of vaccinations and appropriate treatment facilities.
Dr. Ernst von Schwarz, a triple board-certified internist and heart transplant cardiologist at UCLA, was quoted in the New York Post as saying, “In the last few years, we have shifted from what we call reactive medicine to what we now call regenerative medicine using mainly stem cell therapies.”
A revolution is about to occur in the globe that will completely alter everything. The $610 billion anti-aging market that is expected to emerge by 2025 aims to understand the changes and processes that lead to the emergence of age-related illnesses, accidents, and disabilities. This is done to prevent them, lessen the harm they inflict, or delay them.
A gold era in ageing and longevity biotechnology research is currently underway, fueled by billions of dollars in funding from startup capital, the pharmaceutical sector, non-profits, and affluent families.The richest persons in the world, including Jeff Bezos (Amazon), Sam Altman (ChatGPT), Larry Page (Google), or Peter Thiel (PayPal), provide a large portion of the funding for this industry. They fund biotech start-ups that conduct more research into cell reprogramming to restore health so that people might live longer, better lives, all while maintaining a certain level of confidentiality.
